ALKBH3 m1A Demethylase Deficiency Reduces Alzheimer's Amyloid-β Pathology

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) aggregation, mitochondrial dysfunction, and cognitive decline.
• The initial molecular events driving AD pathogenesis remain unclear.
• RNA modifications are increasingly recognized for their roles in neurodevelopment and neurodegeneration.

Purpose of the Study:

• To investigate the role of RNA modifications in Alzheimer's disease pathogenesis using the 5xFAD mouse model.
• To identify specific RNA modifications and their regulators involved in AD progression.

Main Methods:

• Analysis of RNA modification patterns in 5xFAD mice.
• Assessment of the impact of ALKBH3 (a demethylase) modulation on Aβ pathology and cognitive function.
• Investigation of the molecular mechanism linking ALKBH3, m1A modification, and mitophagy.

Main Results:

• N1-methyladenosine (m1A) was identified as the most significantly altered RNA modification in the 5xFAD model.
• Upregulation of the m1A demethylase ALKBH3 was observed.
• Reduction of ALKBH3 levels decreased Aβ plaques and restored cognitive function in mice.
• Elevated ALKBH3 in AD patients impairs neuronal morphology and mitochondrial function by inhibiting mitophagy.
• ALKBH3 was found to remove m1A from PINK1 mRNA, a key regulator of mitophagy.

Conclusions:

• ALKBH3 is causally linked to mitophagy impairment and neuronal dysfunction in Alzheimer's disease.
• ALKBH3 levels are elevated in human AD patients.
• Targeting ALKBH3 represents a mechanistically validated therapeutic strategy for Alzheimer's disease.